SEC Form 4Coverage since Jun 25, 2026
$DFTX insider trading
Over the last 12 months, Definium Therapeutics insiders reported no purchases and 5 sales totaling $2.6M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.6M 5 events
- Events · 12m
- 5 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $DFTX · 12Mvia TradingView
Top insiders · 12m
Wiley Matthew T.Chief Commercial Officer1× · $129K
Roberts BrandiChief Financial Officer1× · $136K
Karlin DanielChief Medical Officer1× · $452K
Sullivan MarkChief Legal Officer1× · $586K
Barrow RobertChief Executive Officer1× · $1.3M
All insider trades
5 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | Sullivan MarkChief Legal Officer · O | ▼ Sale | 13,008 | $45.03 | $586K | -3.9% | plan |
| Jun 25, 2026 | Roberts BrandiChief Financial Officer · O | ▼ Sale | 3,013 | $45.03 | $136K | -1.4% | plan |
| Jun 25, 2026 | Barrow RobertChief Executive Officer · O·D | ▼ Sale | 29,208 | $45.03 | $1.3M | -2.6% | plan |
| Jun 25, 2026 | Karlin DanielChief Medical Officer · O | ▼ Sale | 10,035 | $45.03 | $452K | -2% | plan |
| Jun 25, 2026 | Wiley Matthew T.Chief Commercial Officer · O | ▼ Sale | 2,867 | $45.03 | $129K | -1.6% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $DFTX feed.